CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Sunshine Biopharma Inc.

SBFM
$23M
Micro Cap
NASDAQPharmaceutical Preparations🇺🇸North AmericaFORT LAUDERDALE52 employees

Drugs in Pipeline

41

Phase 3 Programs

18

Upcoming Catalysts

13

Next Catalyst

Mar 10, 2026

30d
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

13 upcoming, 0 past

⭐Phase 3Next

Clifutinib Phase 3 Results Expected

Mar 10, 2026Clifutinib324

Primary completion for Clifutinib trial (NCT05586074) in Leukemia, Acute Myeloid (AML)

Source
Phase 2

Clifutinib Besylate Phase 2 Results Expected

May 15, 2026Clifutinib Besylate133

Primary completion for Clifutinib Besylate trial (NCT05133882) in Acute Myeloid Leukemia, Adult

Source
⭐Phase 3

Matching placebo Phase 3 Results Expected

Jun 30, 2026611 300 mg Q2W180

Primary completion for Matching placebo trial (NCT07042126) in Dermatitis, Atopic

Source
⭐Phase 3

611 Phase 3 Results Expected

Jun 30, 2026611180

Primary completion for 611 trial (NCT07042126) in Dermatitis, Atopic

Source
⭐Phase 3

Pembrolizumab Phase 3 Results Expected

Jul 30, 2026Pembrolizumab420

Primary completion for Pembrolizumab trial (NCT06980272) in Advanced Non-Small Cell Lung Cancer

Source
⭐Phase 3

SSGJ-707 Phase 3 Results Expected

Jul 30, 2026SSGJ-707420

Primary completion for SSGJ-707 trial (NCT06980272) in Advanced Non-Small Cell Lung Cancer

Source
Phase 2

Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) Phase 2 Results Expected

August 2026~Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)124

Primary completion for Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) trial (NCT06324812) in Dermatitis, Atopic

Source
⭐Phase 3

Lerotinib Phase 3 Results Expected

August 2026~Lerotinib416

Primary completion for Lerotinib trial (NCT04415853) in Esophageal Cancer

Source
Phase 2

SSGJ-706 Phase 2 Results Expected

Aug 31, 2026SSGJ-706240

Primary completion for SSGJ-706 trial (NCT07171606) in First-line Advanced NSCLC Patients

Source
⭐Phase 3

Clascoterone Phase 3 Results Expected

October 2026~Clascoterone692

Primary completion for Clascoterone trial (NCT06403501) in Acne Vulgaris

Source
Phase 2

SSGJ-705 Phase 2 Results Expected

Dec 31, 2026SSGJ-705340

Primary completion for SSGJ-705 trial (NCT07022002) in Locally Advanced, Recurrent or Metastatic Malignancies

Source
⭐Phase 3

Placebo Phase 3 Results Expected

Jan 14, 2027608 Q2W500

Primary completion for Placebo trial (NCT07261644) in Ankylosing Spondylitis

Source
⭐Phase 3

608 dose Phase 3 Results Expected

Jan 14, 2027608 dose500

Primary completion for 608 dose trial (NCT07261644) in Ankylosing Spondylitis

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Topical corticosteroid

Phase 3

Dermatitis, Atopic

608 Q2W

Phase 3

Psoriasis

DAG181

Phase 3

Chronic HCV Infection

Clascoterone

Phase 3

Acne Vulgaris

Pembrolizumab

Phase 3

Advanced Non-Small Cell Lung Cancer

Lerotinib

Phase 3

Esophageal Cancer

prefilled liquid etanercept(Yisaipu)

Phase 3

Ankylosing Spondylitis

EPREX®

Phase 3

Renal Anemia

HEC74647PA+HEC110114

Phase 3

Chronic HCV Infection

SOF

Phase 3

Chronic HCV Infection

611

Phase 3

Pulmonary Disease, Chronic Obstructive (COPD)

5% minoxidil foam

Phase 3

Androgenetic Alopecia

SSGJ-707

Phase 3

Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

601 1.25mg

Phase 3

Branch Retinal Vein Occlusion

608 dose

Phase 3

Ankylosing Spondylitis

Clifutinib

Phase 3

Leukemia, Acute Myeloid (AML)

ranibizumab 0.5mg

Phase 3

Branch Retinal Vein Occlusion

610

Phase 3

Asthma

Z650

Phase 2

Esophageal Squamous Cell Carcinoma

626

Phase 2

Systemic Lupus Erythematosus (SLE)

611 Q2W

Phase 2

Dermatitis, Atopic

SSS17

Phase 2

Anemia in Pre-Dialysis Patients

Pemetrexed

Phase 2

First-line Advanced NSCLC Patients

HEC585 dose A

Phase 2

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

RTV

Phase 2

Chronic Hepatitis B

Ranibizuman 0.5 mg

Phase 2

Central Retinal Vein Occlusion

Oxaliplatin

Phase 2

Metastatic Colorectal Cancer

HEC110114 Tablet

Phase 2

Chronic Hepatitis C

HEC169096

Phase 2

Advanced Solid Tumor

Clifutinib Besylate

Phase 2

Acute Myeloid Leukemia, Adult

SSGJ-705

Phase 2

Locally Advanced, Recurrent or Metastatic Malignancies

Injection of humanized nerve growth factor (NGF) antibody

Phase 2

Cancer Pain

SSGJ-706

Phase 2

First-line Advanced NSCLC Patients

GLS4

Phase 2

Chronic HBV Infection

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg

Phase 2

Gout Arthritis

Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)

Phase 2

Dermatitis, Atopic

HEC96719

Phase 2

Non-Alcoholic Steatohepatitis

608

Phase 2

Axial Spondyloarthritis

611 150mg

Phase 2

Dermatitis, Atopic

608 Dose A

Phase 2

Ankylosing Spondylitis

611 300 mg Q2W

Phase 2

Pulmonary Disease, Chronic Obstructive

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals
SBFM News